Terapia antitrombotica nella prevenzione primaria e secondaria della malattia arteriosa coronarica.

Antithrombotic therapy is central to the management of coronary artery disease (CAD), yet its optimal use requires a continuous balance between ischemic protection and bleeding risk. While aspirin has historically been the cornerstone of treatment, contemporary evidence supports a transition toward increasingly individualized strategies across the spectrum of disease. In primary prevention, the role of aspirin remains marginal and is limited to carefully selected high-risk individuals. Following percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) remains the standard of care; however, both its duration and composition are progressively tailored according to patient-spe